Implications of corpus gastritis, atrophy and cyclooxygenase in the development of gastric erosions after curing Helicobacter pylori infection

Digestive and Liver Disease

Volumn 37, Issue 6, 2005, Pages 394-401

  Miyake, K ^a   Tatsuguchi, A ^a   Suzuki, K ^a   Ueki, N ^a   Shinji, Y ^a   Kusunoki, M ^a   Iizumi, T ^a   Hiratsuka, T ^a   Nishigaki, H ^a   Futagami, S ^a   Wada, K ^a   Tsukui, T ^a   Sakamoto, C ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cyclooxygenase; Eradication; Gastric erosions; H. pylori infection

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; RABEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; ATROPHIC GASTRITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ERADICATION THERAPY; FEMALE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; SCORING SYSTEM; STOMACH EROSION; STOMACH MUCOSA; ATROPHY; DRUG COMBINATION; ENZYMOLOGY; GASTRITIS; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PEPTIC ULCER;

AGE FACTORS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ATROPHY; CYCLOOXYGENASE 1; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC MUCOSA; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 20444370462     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.12.012     Document Type: Article

References (48)

1. Tepes B., Kavcic B., Gubina M., and Krizman I. A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication. Hepatogastroenterology 46 (1999) 1746-1750
2. Malfertheiner P., Bayerdorffer E., Diete U., Gil J., Lind T., Misiuna P., et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 13 (1999) 703-712
3. Wong B.C., Lam S.K., Lai K.C., Hu W.H., Ching C.K., Ho J., et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 13 (1999) 303-309
4. Abu-Mahfouz M.Z., Prasad V.M., Santogade P., and Cutler A.F. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 92 (1997) 2025-2028
5. Van der Hulst R.W., Rauws E.A., Koycu B., Keller J.J., Bruno M.J., Tijssen J.G., et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 113 (1997) 1082-1086
6. Axon A.T., O'Morain C.A., Bardhan K.D., Crowe J.P., Beattie A.D., Thompson R.P., et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. Br Med J 314 (1997) 565-568
7. Annibale B., Aprile M.R., D'ambra G., Caruana P., Bordi C., and Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 14 (2000) 625-634
8. Solcia E., Villani L., Fiocca R., Luinetti O., Boldorini R., Trespi E., et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol Suppl 201 (1994) 28-34
9. Hamada H., Haruma K., Mihara M., Kamada T., Yoshihara M., Sumii K., et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 14 (2000) 729-735
10. Mayrand S., Loo V., Beech R., Best L., and Joseph L. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?. Am J Gastroenterol 95 (2000) 914-920
11. Labenz J., Blum A.L., Bayerdorffer E., Meining A., Stolte M., and Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 (1997) 1442-1447
12. Di Mario F., Dal Bo' N., Salandin S., Buda A., Pilotto A., Kusstatscher S., et al. The appearance of GOED in patients with duodenal ulcer after eradication of Helicobacter pylori (Hp) infection: a 4-year prospective study [abstract]. Gut 43 Suppl. 2 (1998) A95
13. Jaup B. Gastroesophageal reflux after cure of H. pylori infection. Gastroenterology 113 (1997) 2019
14. El-Omar E.M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
15. Wu J.C., Chan F.K., Wong S.K., Lee Y.T., Leung W.K., and Sung J.J. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 16 (2002) 545-552
16. Koike T., Ohara S., Sekine H., Iijima K., Kato K., Shimosegawa T., et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 94 (1999) 3468-3472
17. Miyake K., Tsukui T., Futagami S., Tatsuguchi A., Shinoki K., Hiratsuka T., et al. Effect of acid suppression therapy on development of gastric erosions after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 16 Suppl. 2 (2002) 210-216
18. Ohara S., Kato M., Asaka M., and Toyota T. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 33 (1998) 6-13
19. Dixon M.F., Genta R.M., Yardley J.H., and Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston1994. Am J Surg Pathol 20 (1996) 1161-1181
20. Feldman M., Cryer B., Sammer D., Lee E., and Spechler S.J. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 277 6 Pt 1 (1999) G1159-G1164
21. Maeda S., Kanai F., Ogura K., Yoshida H., Ikenoue T., Takahashi M., et al. High seropositivity of anti-CagA antibody in Helicobacter pylori infected patients irrelevant to the presence of peptic ulcers and gastric cancer in Japan. Dig Dis Sci 42 (1997) 1841-1847
22. Maeda S., Ogura K., Yoshida H., Kanai F., Ikenoue T., Kato N., et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori-isolates in Japan. Gut 42 (1998) 338-343
23. Azuma T., Yamakawa A., Yamazaki S., Ohtani M., Ito Y., Muramatsu A., et al. Distinct diversity of the cag pathogenicity island among Helicobacter pylori strains in Japan. J Clin Microbiol 42 (2004) 2508-2517
24. Rokkas T., Ladas S.D., Triantafyllou K., Liatsos C., Petridou E., Papatheodorou G., et al. The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. Am J Med 110 (2001) 703-707
25. Wu J.C., Chan F.K., Ching J.Y., Leung W.K., Hui Y., Leong R., et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 53 (2004) 174-179
26. Sung J.J., Lin S.R., Ching J.Y., Zhou L.Y., To K.F., Wang R.T., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 119 (2000) 7-14
27. Ruiz B., Correa P., Fontham E.T., and Ramakrishnan T. Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol 105 (1996) 96-101
28. Khulusi S., Mendall M.A., Patel P., Levy J., Badve S., and Northfield T.C. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 37 (1995) 319-324
29. Tsukui T., Kashiwagi R., Sakane M., Tabata F., Akamatsu T., Wada K., et al. Aging increases and duodenal ulcer reduces the risk for intestinal metaplasia of the gastric corpus in Japanese patients with dyspepsia. J Gastroenterol Hepatol 16 (2001) 15-21
30. Kuipers E.J., Uyterlinde A.M., Pena A.S., Hazenberg H.J., Bloemena E., Lindeman, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 90 (1995) 1401-1406
31. Schenk B.E., Kuipers E.J., Nelis G.F., Bloemena E., Thijs J.C., Snel P., et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 46 (2000) 615-621
32. Cats A., Schenk B.E., Bloemena E., Roosedaal R., Lindeman J., Biemond I., et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 31 (2000) 684-690
33. Logan R.P., Walker M.M., Misiewicz J.J., Gummett P.A., Karim Q.N., and Baron J.H. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36 (1995) 12-16
34. Labenz J., Tillenburg B., Peitz U., Verdu E., Stolte M., Borsch G., et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 41 (1997) 33-36
35. Meining A., Kiel G., and Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 12 (1998) 735-740
36. Gillen D., Wirz A.A., Ardill J.E., and McColl K.E. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 116 (1999) 239-247
37. Guslandi M., Pellegrini A., and Sorghi M. Gastric mucosal defences in the elderly. Gerontology 45 (1999) 206-208
38. Lee M. Age-related changes in gastric blood flow in rats. Gerontology 42 (1996) 289-293
39. Gronbech J.E., and Lacy E.R. Role of gastric blood flow in impaired defense and repair of aged rat stomachs. Am J Physiol 269 5 Pt 1 (1995) G737-G744
40. Lee M., and Feldman M. Age-related reductions in gastric mucosal prostaglandin levels increase susceptibility to aspirin-induced injury in rats. Gastroenterology 107 (1994) 1746-1750
41. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., and Hawkey C.J. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 47 (2000) 762-770
42. Ferraz J.G., Sharkey K.A., Reuter B.K., Asfaha S., Tigley A.W., Brown M.L., et al. Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage. Gastroenterology 113 (1997) 195-204
43. Wallace J.L., McKnight W., Reuter B.K., and Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
44. Gretzer B., Maricic N., Respondek M., Schuligoi R., and Peskar B.M. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 132 (2001) 1565-1573
45. Halter F., Tarnawski A.S., Schmassmann A., and Peskar B.M. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49 (2001) 443-453
46. Tatsuguchi A., Sakamoto C., Wada K., Akamatsu T., Tsukui T., Miyake K., et al. Localisation of cyclooxygenase-1 and cyclooxygenase-2 in Helicobacter pylori-related gastritis and gastric ulcer tissues in humans. Gut 46 (2000) 782-789
47. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112 (1997) 387-397
48. Miyake K., Tsukui T., Wada K., Tatsuguchi A., Futagami S., Hiratsuka T., et al. Irritant-induced cyclooxygenase-2 is involved in the defense mechanism of the gastric mucosa in mice. J Gastroenterol 37 (2002) 164-171